Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin

Last updated: May 28, 2024
Sponsor: Rao Dermatology
Overall Status: Active - Recruiting

Phase

4

Condition

N/A

Treatment

Roflumilast

Vehicle (Roflumilast 0.3% vehicle cream)

Clinical Study ID

NCT06440473
Pro00078950
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of deposition within the epidermal and dermal layers compared to the vehicle. Specifically, we anticipate observing deeper penetration and more uniform distribution of roflumilast within the skin layers, indicative of enhanced efficacy, as visualized by LC-OCT imaging.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy subjects over 18 years of age from the outpatient dermatology clinic, RaoDermatology. All subjects must have provided written informed consent.

Exclusion

Exclusion Criteria:

  • Subjects with a history of immune-mediated skin conditions will be excluded fromparticipation. Additionally, participants who have received systemic therapy withinthe last 60 days will not be eligible. Those using topical therapy must havediscontinued their current treatment for a minimum of seven days prior toenrollment.

Study Design

Total Participants: 3
Treatment Group(s): 2
Primary Treatment: Roflumilast
Phase: 4
Study Start date:
May 28, 2024
Estimated Completion Date:
July 28, 2024

Study Description

Primary Objective

Compare the deposition of Zoryve and the vehicle in the epidermal and dermal layers using LC-OCT.

Primary Endpoint

The primary endpoint of this study is a visual qualitative analysis of LC-OCT images conducted by an expert confocalist, Babar Rao MD. This analysis aims to assess the penetration of the active drug product compared to the vehicle.

Subjects will be instructed to apply topical 0.3% Zoryve once daily for seven consecutive days to a predetermined 2x2cm area on the dorsal surface forearm, as defined by the investigator. Additionally, participants will apply a topical cream vehicle provided by Zoryve to the dorsall side of the opposite forearm. Therefore, one forearm, will be designated for application of Zoryve, while the other forearm will the designated for application of the topical cream vehicle supplied by Zoryve. Subjects will apply the topical vehicle and roflumilast, daily, for 7 consecutive days. LC-OCT imaging will be conducted on both arms at various time points: baseline (T0A), 15 minutes (T0B), 1 hour (T0C), 8-12 hours (T0D), 24 hours (T0E), seven days after application (T7), and seven days after not applying cream (T14). LC-OCT imaging will follow a predefined image acquisition protocol, with investigators designating 2x2cm areas for imaging. The imaging protocol will include capturing 2D vertical photos, 3D photos, and 2D vertical videos per imaging site. Participants will be instructed to photograph the imaging sites to aid in the accurate application of the active drug product or vehicle cream base.

Connect with a study center

  • Rao Dermatology

    Atlantic Highlands, New Jersey 07716
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.